| Identification | Back Directory | [Name]
4-Piperidinamine, 1-(2-benzoxazolylmethyl)-N-[(4-methoxyphenyl)methyl]-, hydrochloride (1:2) | [CAS]
1186049-44-4 | [Synonyms]
DDO-02005
4-Piperidinamine, 1-(2-benzoxazolylmethyl)-N-[(4-methoxyphenyl)methyl]-, hydrochloride (1:2) | [Molecular Formula]
C21H26ClN3O2 | [MOL File]
1186049-44-4.mol | [Molecular Weight]
387.91 |
| Hazard Information | Back Directory | [Uses]
DDO-02005 is a potent Kv1.5 potassium channel inhibitor with an IC50 value of 0.72 μM. DDO-02005 has good anti-atrial fibrillation (AF) effect in CaCl2-ACh AF rats model and effective anti-arrhythmic activity caused by aconitine[1]. | [in vivo]
DDO-02005 (0.1, 1, 3, 9 mg/kg; IV, single dosage) effectively combat the arrhythmogenic toxicity of aconitine in rats[1].
Pharmacokinetic Parameters of DDO-02005 in Sprague-Dawley rats[1].
| IV (1 mg/kg) | PO (1.25 mg/kg) | | t1/2 (h) | 3.23 ± 1.07 | 6.25 ± 2.40 | | Cmax (μg/L) | 90.23 ± 28.83 | 1.27 ± 0.40 | | AUC0-t (μg/L·h) | 178.42 ± 39.33 | 4.41 ± 0.69 | | CL (L/h/kg) | 5.83 ± 1.44 | 36.51 ± 2.54 |
| [References]
[1] Zhao L, et al. Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):462-471. DOI:10.1080/14756366.2021.2018683 |
|
|